Soluble Epoxide Hydrolase Inhibitors and Heart Failure

Cardiovascular Therapeutics

Volumn 29, Issue 2, 2011, Pages 99-111

  Qiu, Hong ^a   Li, Ning ^a   Liu, Jun Yan ^c   Harris, Todd R ^c   Hammock, Bruce D ^c   Chiamvimonvat, Nipavan ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiac hypertrophy; Cytochrome P450; Epoxyeicosatrienoic acids (EETs); Heart failure; Soluble epoxide hydrolase inhibitors

Indexed keywords

1 (1 METHANESULFONYL PIPERIDIN 4 YL) 3 (4 TRIFLUOROMETHOXY PHENYL)UREA; 1 (1 NICOTINOYLPIPERIDIN 4 YL) 3 [4 (TRIFLUOROMETHOXY)PHENYL]UREA; 1 ADAMANTANYL 3 [5 [2 (2 ETHOXYETHOXY)ETHOXY]PENTYL]UREA; 1 CYCLOHEXYL 3 DODECYL UREA; 12 (3 ADAMANTAN 1 YL UREIDO)DODE CANOIC ACID; 12 (3 ADAMANTAN 1 YL UREIDO)DODECANOIC ACID BUTYL ESTER; 4 [4 (3 ADAMANTAN 1 YL UREIDO)CYCLOHEXYLOXY]BENZOIC ACID; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; AR 9276; EPOXIDE HYDROLASE; HYDROLASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG; ENZYME INHIBITOR;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BIOAVAILABILITY; CARDIOVASCULAR DISEASE; DRUG MECHANISM; DRUG STRUCTURE; HEART FAILURE; HEART HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; UNSPECIFIED SIDE EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOMEGALY; GENETICS; MYOCARDIAL REPERFUSION INJURY; PHYSIOLOGY;

ANIMALS; CARDIOMEGALY; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HEART FAILURE; HUMANS; MYOCARDIAL REPERFUSION INJURY; VENTRICULAR REMODELING;

EID: 79952020273     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00150.x     Document Type: Review

References (109)

1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics - 2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-e171.
2. Frey N, Olson EN. Cardiac hypertrophy: The good, the bad, and the ugly. Annu Rev Physiol 2003;65:45-79.
3. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-1435.
4. Mendez M, LaPointe MC. Trophic effects of the cyclooxygenase-2 product prostaglandin E(2) in cardiac myocytes. Hypertension 2002;39:382-388.
5. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999;285:1276-1279.
6. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996;78:415-423.
7. Gauthier KM, Edwards EM, Falck JR, Reddy DS, Campbell WB. 14, 15-epoxyeicosatrienoic acid represents a transferable endothelium-dependent relaxing factor in bovine coronary arteries. Hypertension 2005;45:666-671.
8. Rosolowsky M, Campbell WB. Role of PGI2 and epoxyeicosatrienoic acids in relaxation of bovine coronary arteries to arachidonic acid. Am J Physiol 1993;264:H327-H335.
9. Gebremedhin D, Harder DR, Pratt PF, Campbell WB. Bioassay of an endothelium-derived hyperpolarizing factor from bovine coronary arteries: Role of a cytochrome P450 metabolite. J Vasc Res 1998;35:274-284.
10. Fang X, Kaduce TL, Weintraub NL, VanRollins M, Spector AA. Functional implications of a newly characterized pathway of 11, 12-epoxyeicosatrienoic acid metabolism in arterial smooth muscle. Circ Res 1996;79:784-793.
11. Fang X, Kaduce TL, Weintraub NL, Spector AA. Cytochrome P450 metabolites of arachidonic acid: Rapid incorporation and hydration of 14, 15-epoxyeicosatrienoic acid in arterial smooth muscle cells. Prostaglandins Leukot Essent Fatty Acids 1997;57:367-371.
12. Eckman DM, Hopkins N, McBride C, Keef KD. Endothelium-dependent relaxation and hyperpolarization in guinea-pig coronary artery: Role of epoxyeicosatrienoic acid. Br J Pharmacol 1998;124:181-189.
13. Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL, Hammock BD. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat 2007;82:42-49.
14. Spiecker M, Liao JK. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 2005;433:413-420.
15. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002;82:131-185.
16. Spiecker M, Darius H, Hankeln T, et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004;110:2132-2136.
17. + channels and p42/p44 MAPK pathway. Circ Res 2004;95:506-514.
18. Zhang Y, El-Sikhry H, Chaudhary KR, et al. Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 2009;297:H37-H46.
19. Yu Z, Xu F, Huse LM, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 2000;87:992-998.
20. Marino JP, Jr. Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery. Curr Top Med Chem 2009;9:452-463.
21. Gross GJ, Nithipatikom K. Soluble epoxide hydrolase: A new target for cardioprotection. Curr Opin Investig Drugs 2009;10:253-258.
22. Chiamvimonvat N, Ho CM, Tsai HJ, Hammock BD. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol 2007;50:225-237.
23. Imig JD. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardiovasc Drug Rev 2006;24:169-188.
24. Larsen BT, Gutterman DD, Hatoum OA. Emerging role of epoxyeicosatrienoic acids in coronary vascular function. Eur J Clin Invest 2006;36:293-300.
25. Ai D, Pang W, Li N, et al. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci U S A 2009;106:564-569.
26. Batchu SN, Law E, Brocks DR, Falck JR, Seubert JM. Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. J Mol Cell Cardiol 2009;46:67-74.
27. Motoki A, Merkel MJ, Packwood WH, et al. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am J Physiol Heart Circ Physiol 2008;295:H2128-H2134.
28. Ulu A, Davis BB, Tsai HJ, et al. Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J Cardiovasc Pharmacol 2008;52:314-323.
29. Li J, Carroll MA, Chander PN, Falck JR, Sangras B, Stier CT. Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. Front Biosci 2008;13:3480-3487.
30. Gross GJ, Gauthier KM, Moore J, Falck JR, Hammock BD, Campbell WB, Nithipatikom K. Effects of the selective EET antagonist, 14, 15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ Physiol 2008;294:H2838-H2844.
31. Seubert JM, Sinal CJ, Graves J, et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 2006;99:442-450.
32. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 2002;39:690-694.
33. Xu D, Li N, He Y, et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A 2006;103:18733-18738.
34. Li N, Liu JY, Timofeyev V, et al. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches. J Mol Cell Cardiol 2009;47:835-845.
35. Morisseau C, Hammock BD. Epoxide hydrolases: Mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol 2005;45:311-333.
36. Oesch F, Schladt L, Hartmann R, Timms C, Worner W. Rat cytosolic epoxide hydrolase. Adv Exp Med Biol 1986;197:195-201.
37. Morisseau C, Hammock BD. Gerry Brooks and epoxide hydrolases: Four decades to a pharmaceutical. Pest Manag Sci 2008;64:594-609.
38. Beetham JK, Tian T, Hammock BD. cDNA cloning and expression of a soluble epoxide hydrolase from human liver. Arch Biochem Biophys 1993;305:197-201.
39. Newman JW, Morisseau C, Hammock BD. Epoxide hydrolases: Their roles and interactions with lipid metabolism. Prog Lipid Res 2005;44:1-51.
40. Beetham JK, Grant D, Arand M, et al. Gene evolution of epoxide hydrolases and recommended nomenclature. DNA Cell Biol 1995;14:61-71.
41. Cronin A, Mowbray S, Durk H, et al. The N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase. Proc Natl Acad Sci U S A 2003;100:1552-1557.
42. Decker M, Arand M, Cronin A. Mammalian epoxide hydrolases in xenobiotic metabolism and signalling. Arch Toxicol 2009;83:297-318.
43. Argiriadi MA, Morisseau C, Hammock BD, Christianson DW. Detoxification of environmental mutagens and carcinogens: Structure, mechanism, and evolution of liver epoxide hydrolase. Proc Natl Acad Sci U S A 1999;96:10637-10642.
44. Gomez GA, Morisseau C, Hammock BD, Christianson DW. Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis. Biochemistry 2004;43:4716-4723.
45. Borhan B, Jones AD, Pinot F, Grant DF, Kurth MJ, Hammock BD. Mechanism of soluble epoxide hydrolase. Formation of an alpha-hydroxy ester-enzyme intermediate through Asp-333. J Biol Chem 1995;270:26923-26930.
46. Sandberg M, Meijer J. Structural characterization of the human soluble epoxide hydrolase gene (EPHX2). Biochem Biophys Res Commun 1996;221:333-339.
47. Hammock BD, Ota K. Differential induction of cytosolic epoxide hydrolase, microsomal epoxide hydrolase, and glutathione S-transferase activities. Toxicol Appl Pharmacol 1983;71:254-265.
48. Pinot F, Grant DF, Spearow JL, Parker AG, Hammock BD. Differential regulation of soluble epoxide hydrolase by clofibrate and sexual hormones in the liver and kidneys of mice. Biochem Pharmacol 1995;50:501-508.
49. Tanaka H, Kamita SG, Wolf NM, Harris TR, Wu Z, Morisseau C, Hammock BD. Transcriptional regulation of the human soluble epoxide hydrolase gene EPHX2. Biochim Biophys Acta 2008;1779:17-27.
50. Denlinger CL, Vesell ES. Hormonal regulation of the developmental pattern of epoxide hydrolases. Studies in rat liver. Biochem Pharmacol 1989;38:603-610.
51. Inoue N, Fujiwara K, Iwata T, Imai K, Aimoto T. Involvement of pituitary hormone in the sex-related regulation of hepatic epoxide hydrolase activity in mice. Biol Pharm Bull 1995;18:536-539.
52. Inoue N, Yamada K, Imai K, Aimoto T. Sex hormone-related control of hepatic epoxide hydrolase activities in mice. Biol Pharm Bull 1993;16:1004-1007.
53. Kaur S, Gill SS. Age-related changes in the activities of epoxide hydrolases in different tissues of mice. Drug Metab Dispos 1985;13:711-715.
54. Monti J, Fischer J, Paskas S, et al. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet 2008;40:529-537.
55. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 2000;275:40504-40510.
56. Luria A, Weldon SM, Kabcenell AK, et al. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem 2007;282:2891-2898.
57. Sandberg M, Hassett C, Adman ET, Meijer J, Omiecinski CJ. Identification and functional characterization of human soluble epoxide hydrolase genetic polymorphisms. J Biol Chem 2000;275:28873-28881.
58. Saito S, Iida A, Sekine A, Eguchi C, Miura Y, Nakamura Y. Seventy genetic variations in human microsomal and soluble epoxide hydrolase genes (EPHX1 and EPHX2) in the Japanese population. J Hum Genet 2001;46:325-329.
59. Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, et al. Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol 2003;64:482-490.
60. Lee CR, North KE, Bray MS, et al. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 2006;15:1640-1649.
61. Fornage M, Hinojos CA, Nurowska BW, Boerwinkle E, Hammock BD, Morisseau CH, Doris PA. Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension 2002;40:485-490.
62. Corenblum MJ, Wise VE, Georgi K, Hammock BD, Doris PA, Fornage M. Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat. Hypertension 2008;51:567-573.
63. Morisseau C, Du G, Newman JW, Hammock BD. Mechanism of mammalian soluble epoxide hydrolase inhibition by chalcone oxide derivatives. Arch Biochem Biophys 1998;356:214-228.
64. Magdalou J, Hammock BD. 1, 2-Epoxycycloalkanes: Substrates and inhibitors of microsomal and cytosolic epoxide hydrolases in mouse liver. Biochem Pharmacol 1988;37:2717-2722.
65. Morisseau C, Goodrow MH, Dowdy D, Zheng J, Greene JF, Sanborn JR, Hammock BD. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc Natl Acad Sci U S A 1999;96:8849-8854.
66. Morisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL, Hammock BD. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol 2002;63:1599-1608.
67. Argiriadi MA, Morisseau C, Goodrow MH, Dowdy DL, Hammock BD, Christianson DW. Binding of alkylurea inhibitors to epoxide hydrolase implicates active site tyrosines in substrate activation. J Biol Chem 2000;275:15265-15270.
68. Nakagawa Y, Wheelock CE, Morisseau C, Goodrow MH, Hammock BG, Hammock BD. 3-D QSAR analysis of inhibition of murine soluble epoxide hydrolase (MsEH) by benzoylureas, arylureas, and their analogues. Bioorg Med Chem 2000;8:2663-2673.
69. McElroy NR, Jurs PC, Morisseau C, Hammock BD. QSAR and classification of murine and human soluble epoxide hydrolase inhibition by urea-like compounds. J Med Chem 2003;46:1066-1080.
70. Kim IH, Morisseau C, Watanabe T, Hammock BD. Design, synthesis, and biological activity of 1, 3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J Med Chem 2004;47:2110-2122.
71. Kim IH, Heirtzler FR, Morisseau C, Nishi K, Tsai HJ, Hammock BD. Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem 2005;48:3621-3629.
72. Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 2007;50:3825-3840.
73. Jones PD, Tsai HJ, Do ZN, Morisseau C, Hammock BD. Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett 2006;16:5212-5216.
74. Harris TR, Li N, Chiamvimonvat N, Hammock BD. The potential of soluble epoxide hydrolase inhibition in the treatment of cardiac hypertrophy. Congest Heart Fail 2008;14:219-224.
75. Liu JY, Tsai HJ, Hwang SH, Jones PD, Morisseau C, Hammock BD. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. Br J Pharmacol 2009;156:284-296.
76. Zhao X, Yamamoto T, Newman JW, et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 2004;15:1244-1253.
77. Imig JD, Zhao X, Zaharis CZ, et al. An Orally Active Epoxide Hydrolase Inhibitor Lowers Blood Pressure and Provides Renal Protection in Salt-Sensitive Hypertension. Hypertension 2005;46:975-981.
78. Jung O, Brandes RP, Kim IH, et al. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 2005;45:759-765.
79. Shen HC, Ding FX, Deng Q, et al. Discovery of 3, 3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett 2009;19:5314-5320.
80. Shen HC, Ding FX, Wang S, et al. Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett 2009;19:3398-3404.
81. Zhang LN, Vincelette J, Cheng Y, et al. Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia. Arterioscler Thromb Vasc Biol 2009;29:1265-1270.
82. Tang X, Holmes BB, Nithipatikom K, Hillard CJ, Kuhn H, Campbell WB. Reticulocyte 15-lipoxygenase-I is important in acetylcholine-induced endothelium-dependent vasorelaxation in rabbit aorta. Arterioscler Thromb Vasc Biol 2006;26:78-84.
83. Yang B, Graham L, Dikalov S, Mason RP, Falck JR, Liao JK, Zeldin DC. Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol 2001;60:310-320.
84. Nithipatikom K, Moore JM, Isbell MA, Falck JR, Gross GJ. Epoxyeicosatrienoic acids in cardioprotection: Ischemic versus reperfusion injury. Am J Physiol Heart Circ Physiol 2006;291:H537-H542.
85. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J Biol Chem 1999;274:27339-27342.
86. Karin M. How NF-kappaB is activated: The role of the IkappaB kinase (IKK) complex. Oncogene 1999;18:6867-6874.
87. Rothwarf DM, Karin M. The NF-kappa B activation pathway: A paradigm in information transfer from membrane to nucleus. Sci STK 1999;1999:RE1.
88. Campbell WB. New role for epoxyeicosatrienoic acids as anti-inflammatory mediators. Trends Pharmacol Sci 2000;21:125-127.
89. Nichols TC. NF-kappaB and reperfusion injury. Drug News Perspect 2004;17:99-104.
90. Hall G, Hasday JD, Rogers TB. Regulating the regulator: NF-kappaB signaling in heart. J Mol Cell Cardiol 2006;41:580-591.
91. Purcell NH, Molkentin JD. Is nuclear factor kappaB an attractive therapeutic target for treating cardiac hypertrophy? Circulation 2003;108:638-640.
92. Freund C, Schmidt-Ullrich R, Baurand A, et al. Requirement of nuclear factor-kappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation 2005;111:2319-2325.
93. Sarman B, Skoumal R, Leskinen H, et al. Nuclear factor-kappaB signaling contributes to severe, but not moderate, angiotensin II-induced left ventricular remodeling. J Hypertens 2007;25:1927-1939.
94. Satoh M, Minami Y, Takahashi Y, Nakamura M. Immune modulation: Role of the inflammatory cytokine cascade in the failing human heart. Curr Heart Fail Rep 2008;5:69-74.
95. Sekiguchi K, Li X, Coker M, Flesch M, Barger PM, Sivasubramanian N, Mann DL. Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. Cardiovasc Res 2004;63:433-442.
96. Schmelzer KR, Inceoglu B, Kubala L, Kim IH, Jinks SL, Eiserich JP, Hammock BD. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A 2006;103:13646-13651.
97. Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, Hammock BD. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A 2005;102:9772-9777.
98. Dhanasekaran A, Gruenloh SK, Buonaccorsi JN, et al. Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. Am J Physiol Heart Circ Physiol 2008;294:H724-H735.
99. + channels in pressure overload-induced congestive heart failure revealed in KCNJ11 Kir6.2-null mutant. J Physiol 2006;577:1053-1065.
100. + channels in the cardiac inner mitochondrial membrane. Science 2002;298:1029-1033.
101. + channels and myocardial preconditioning. Circ Res 1999;84:973-979.
102. Hanley PJ, Daut J. K(ATP) channels and preconditioning: A re-examination of the role of mitochondrial K(ATP) channels and an overview of alternative mechanisms. J Mol Cell Cardiol 2005;39:17-50.
103. Nabauer M, Kaab S. Potassium channel down-regulation in heart failure. Cardiovasc Res 1998;37:324-334.
104. Eisner DA, Dibb KM, Trafford AW. The mechanism and significance of the slow changes of ventricular action potential duration following a change of heart rate. Exp Physiol 2009;94:520-528.
105. Owen AJ, Peter-Przyborowska BA, Hoy AJ, McLennan PL. Dietary fish oil dose- and time-response effects on cardiac phospholipid fatty acid composition. Lipids 2004;39:955-961.
106. VanRollins M. Epoxygenase metabolites of docosahexaenoic and eicosapentaenoic acids inhibit platelet aggregation at concentrations below those affecting thromboxane synthesis. J Pharmacol Exp Ther 1995;274:798-804.
107. Ye D, Zhang D, Oltman C, Dellsperger K, Lee HC, VanRollins M. Cytochrome p-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels. J Pharmacol Exp Ther 2002;303:768-776.
108. Pokreisz P, Fleming I, Kiss L, et al. Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension 2006;47:762-770.
109. Hutchens MP, Nakano T, Dunlap J, Traystman RJ, Hurn PD, Alkayed NJ. Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation. Resuscitation 2008;76:89-94.